Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone

British Journal of Haematology

Volumn 114, Issue 4, 2001, Pages 800-809

  Di Gaetano, N ^a   Xiao, Y ^a   Erba, E ^a   Bassan, R ^a   Rambaldi, A ^a   Golay, J ^a   Introna, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Chemotherapeutic agent; Complement; Fludarabine; Lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD59 ANTIGEN; CISPLATIN; COMPLEMENT; DECAY ACCELERATING FACTOR; DOXORUBICIN; FLUDARABINE; IDARUBICIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PACLITAXEL; RITUXIMAB;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CISPLATIN; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOXORUBICIN; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IDARUBICIN; IN SITU NICK-END LABELING; LEUKEMIA, B-CELL, CHRONIC; LYMPHOMA, FOLLICULAR; PACLITAXEL; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 0034796371     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03014.x     Document Type: Article

References (39)

1. Fludarabine, an update of its pharmacology and use in the treatment of haematological malignancies
2. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
3. Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to Rituximab therapy
4. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells
5. Chemotherapy of neoplastic diseases
6. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors
7. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
8. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
9. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia
10. Phase II study of Rituximab in combination with Fludarabine in patients (pts) with low grade or follicular B cell lymphoma
11. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
12. Treatment of patients with low-grade B-cell lymphoma with the combination of chimaeric anti-CD20 monoclonal antibody and CHOP chemotherapy
13. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
14. Rituximab anti-CD20 monoclonal antibody therapy in non hodgkin's lymphoma: Safety and efficacy of retreatment
15. Combination immunotherapy of relapsed or refractory low grade or follicular non-Hodgkin's lymphoma with Rituximab and interferon-alpha-2a
16. Chimaeric anti-CD20 (IDC-C2B8) monoclonal antibody sensitises a B cell lymphoma cell line to cell killing by cytotoxic drugs
17. Apoptosis in cancer therapy: Crossing the threshold
18. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
19. Relapsed follicular lymphoma. Response to Fludarabine-Mitoxantrone regimen and monoclonal anti-CD20 (Rituximab)
20. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
21. Fludarabine ability to down-regulate Bcl-2 gene product in CD51 leukaemic B cells: In vitro/in vivo correlations
22. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
23. Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism
24. Fludarabine and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
25. Inhibition of RNA transcription: A biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine
26. Homologous and heterologous desensitization of proto-oncogene c-fos expression in murine peritoneal macrophages
27. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with In vitro and In vivo chemoresponses
28. Control of the complement system
29. Rituximab anti-CD20 antibody therapy of B cell non-Hodgkin's lymphomas
30. Rituximab chimaeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
31. Clinical status and optimal use of rituximab for B-cell lymphomas
32. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55) as a covalently cross-linked dimer
33. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms
34. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies
35. Combined Fludarabine and Rituximab for low grade lymphoproliferative disorders
36. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
37. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
38. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL60 cellular RNA and DNA
39. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)